PRL and prostate cancer: Compared with control group, there were remarkable differences in endocrine resistance (Androstenedione), tryptophan metabolism pathways (2-Aminophenol, 4-Hydroxy-2-quinolinecarboxylic acid), prostate cancer (Androstenedione) and Prolactin signaling pathway (Androstenedione) in WAS rats.